Filing Details

Accession Number:
0001415889-24-004625
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-21 16:31:47
Reporting Period:
2024-02-16
Accepted Time:
2024-02-21 16:31:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1528115 Annexon Inc. ANNX Pharmaceutical Preparations (2834) 275414423
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1818525 Ted Yednock C/O Annexon, Inc
1400 Sierra Point Pkwy, Bldg C, Ste 200
Brisbane CA 94005
Evp & Chief Innovation Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-16 39,000 $0.00 75,075 No 4 A Direct
Common Stock Disposition 2024-02-20 2,604 $5.51 72,471 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-02-16 160,000 $0.00 160,000 $5.13
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
160,000 2034-02-16 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 21,000 Indirect By Spouse
Footnotes
  1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025.
  2. The shares were sold to cover tax withholding obligations in connection with the vesting of RSUs.
  3. This transaction was executed in multiple trades in prices ranging from $5.34 to $5.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.